The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

Yue Pan; Chao Deng; Zhenhua Qiu; Chenghui Cao; Fang Wu

doi:10.3389/fonc.2021.713530

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

Front Oncol. 2021 Oct 1:11:713530. doi: 10.3389/fonc.2021.713530. eCollection 2021.

Authors

Yue Pan¹, Chao Deng¹, Zhenhua Qiu¹, Chenghui Cao², Fang Wu^{1

3

4

5}

Affiliations

¹ Department of Oncology, Second Xiangya Hospital, Central South University, Changsha, China.
² Central South University, Changsha, China.
³ Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha, China.
⁴ Hunan Key Laboratory of Tumor Models and Individualized Medicine, Second Xiangya Hospital, Central South University, Changsha, China.
⁵ Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital, Central South University, Changsha, China.

Abstract

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly improved survival benefits. However, the clinical benefits of targeting ALK using TKIs are limited due to the emergence of drug resistance. The landscape of resistance mechanisms and treatment decisions has become increasingly complex. Therefore, continued research into new drugs and combinatorial therapies is required to improve outcomes in NSCLC. In this review, we explore the resistance mechanisms of ALK TKIs in advanced NSCLC in order to provide a theoretical basis and research ideas for solving the problem of ALK drug resistance.

Keywords: NSCLC; TKI - tyrosine kinase inhibitor; anaplastic lymphoma kinase (ALK); resistance; therapy.

Publication types

Review